# Open-Label Extension Study to Evaluate the Long Term Safety and Efficacy of ESK-001 in Plaque Psoriasis

> **NCT05739435** · PHASE2 · ACTIVE_NOT_RECRUITING · sponsor: **Alumis Inc** · enrollment: 165 (actual)

## Conditions studied

- Plaque Psoriasis

## Interventions

- **DRUG:** envudeucitinib

## Key facts

- **NCT ID:** NCT05739435
- **Lead sponsor:** Alumis Inc
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2023-01-17
- **Primary completion:** 2026-12-01
- **Final completion:** 2026-12-30
- **Target enrollment:** 165 (ACTUAL)
- **Last updated:** 2026-04-01


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05739435

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05739435, "Open-Label Extension Study to Evaluate the Long Term Safety and Efficacy of ESK-001 in Plaque Psoriasis". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT05739435. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*